Detected ·
Braveheart Bio
$382.5M—
Braveheart Bio, a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, has announced the pricing of its upsized IPO on Nasdaq (ticker: BRVE) at $18.00 per share, with expected gross proceeds of approximately $382.5M.
- Website
- www.braveheart.bio
- Amount
- $382 500 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-06 16:07:11 UTC
- Signal ID
- 6cbd1f82-00c2-4c65-998c-d64bf7be59c9
As the API returns it
{
"id": "6cbd1f82-00c2-4c65-998c-d64bf7be59c9",
"created_at": "2026-08-06T16:07:11.317303Z",
"company_name": "Braveheart Bio",
"company_website_url": "www.braveheart.bio",
"company_linkedin_url": "https://www.linkedin.com/company/braveheart-bio",
"event_type": "funding",
"funding_amount": 382500000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Braveheart Bio, a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, has announced the pricing of its upsized IPO on Nasdaq (ticker: BRVE) at $18.00 per share, with expected gross proceeds of approximately $382.5M.*"
}